ATE535529T1 - Verfahren zur acylierung von maytansinol mit chiralen aminosäuren - Google Patents
Verfahren zur acylierung von maytansinol mit chiralen aminosäurenInfo
- Publication number
- ATE535529T1 ATE535529T1 AT06800952T AT06800952T ATE535529T1 AT E535529 T1 ATE535529 T1 AT E535529T1 AT 06800952 T AT06800952 T AT 06800952T AT 06800952 T AT06800952 T AT 06800952T AT E535529 T1 ATE535529 T1 AT E535529T1
- Authority
- AT
- Austria
- Prior art keywords
- maytansinol
- acylation
- amino acids
- chiral amino
- chiral
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- QWPXBEHQFHACTK-RZKXNLMUSA-N CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-RZKXNLMUSA-N 0.000 title 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 title 1
- 230000010933 acylation Effects 0.000 title 1
- 238000005917 acylation reaction Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006345 epimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70669405P | 2005-08-09 | 2005-08-09 | |
| PCT/US2006/030857 WO2007021674A2 (en) | 2005-08-09 | 2006-08-08 | Method of acylating maytansinol with chiral amino acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535529T1 true ATE535529T1 (de) | 2011-12-15 |
Family
ID=37758086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06800952T ATE535529T1 (de) | 2005-08-09 | 2006-08-08 | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7598375B2 (de) |
| EP (1) | EP1913002B9 (de) |
| JP (1) | JP5167130B2 (de) |
| AT (1) | ATE535529T1 (de) |
| AU (1) | AU2006280146B2 (de) |
| CA (1) | CA2617953C (de) |
| WO (1) | WO2007021674A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| PE20090943A1 (es) | 2007-07-16 | 2009-08-05 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
| EP2176295B1 (de) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanisierte anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| KR101607346B1 (ko) | 2008-01-31 | 2016-03-29 | 제넨테크, 인크. | 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법 |
| RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| US20120121615A1 (en) * | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| JP5826863B2 (ja) | 2011-02-15 | 2015-12-02 | イミュノジェン・インコーポレーテッド | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP6209159B2 (ja) | 2011-06-21 | 2017-10-04 | イミュノジェン・インコーポレーテッド | ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体 |
| MX353958B (es) | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| LT3486248T (lt) * | 2012-09-26 | 2021-08-25 | Immunogen, Inc. | Patobulinti maitansinolio acilinimo būdai |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) * | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN104530235A (zh) | 2012-12-21 | 2015-04-22 | 百奥泰生物科技(广州)有限公司 | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 |
| EP2948478B1 (de) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antikörper gegen cdh19 für melanome |
| EP3566750A3 (de) | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Konjugate aus zellbindenden und zytotoxischen verbindungen |
| JP6847388B2 (ja) | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN105585579A (zh) * | 2014-10-24 | 2016-05-18 | 南京联宁生物制药有限公司 | 一种化合物及其制备方法以及美登素dm1的制备方法 |
| CN104623687B (zh) * | 2015-03-11 | 2017-09-05 | 中国科学院上海高等研究院 | 利用美登醇制备的抗体药物偶联物及其制备方法和应用 |
| MX376146B (es) | 2015-03-17 | 2025-03-07 | Regeneron Pharma | Reactivos de acilacion de aminoacidos y metodos para usar los mismos. |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法 |
| US11420981B2 (en) | 2019-04-18 | 2022-08-23 | Indena S.P.A. | Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof |
| EP4587445A1 (de) * | 2022-09-16 | 2025-07-23 | ImmunoGen, Inc. | Verbesserte verfahren zur herstellung von maytansinol-n-methylalaninestern |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260609A (en) | 1977-06-01 | 1981-04-07 | Merck & Co., Inc. | Di- and tri- substituted thiazoles |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7771727B2 (en) | 2002-03-01 | 2010-08-10 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US7301019B2 (en) * | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
-
2006
- 2006-08-08 AT AT06800952T patent/ATE535529T1/de active
- 2006-08-08 EP EP06800952A patent/EP1913002B9/de active Active
- 2006-08-08 AU AU2006280146A patent/AU2006280146B2/en active Active
- 2006-08-08 CA CA2617953A patent/CA2617953C/en active Active
- 2006-08-08 JP JP2008526125A patent/JP5167130B2/ja active Active
- 2006-08-08 US US11/500,378 patent/US7598375B2/en active Active
- 2006-08-08 WO PCT/US2006/030857 patent/WO2007021674A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20070037972A1 (en) | 2007-02-15 |
| WO2007021674A3 (en) | 2007-07-26 |
| EP1913002B9 (de) | 2012-04-25 |
| AU2006280146A1 (en) | 2007-02-22 |
| WO2007021674A2 (en) | 2007-02-22 |
| CA2617953A1 (en) | 2007-02-22 |
| EP1913002A4 (de) | 2010-10-27 |
| JP2009504655A (ja) | 2009-02-05 |
| CA2617953C (en) | 2013-12-17 |
| EP1913002A2 (de) | 2008-04-23 |
| AU2006280146B2 (en) | 2012-06-28 |
| JP5167130B2 (ja) | 2013-03-21 |
| US7598375B2 (en) | 2009-10-06 |
| EP1913002B1 (de) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE535529T1 (de) | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren | |
| DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
| ATE475419T1 (de) | Verfahren zur zubereitung von lansoprazol | |
| DE602004032160D1 (de) | Verfahren zur Zubereitung von Getränken | |
| DE602004002519D1 (de) | Verfahren zur Oberflächenbehandlung von Metallen | |
| EP1912674B8 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
| DE602005016292D1 (de) | Verfahren zur herstellung von glatiramer | |
| EP1877175A4 (de) | Vorrichtung und verfahren zur herstellung von radiopharmazeutika | |
| DE60321130D1 (de) | Variation von parametern zur neurostimulation | |
| DE502004001613D1 (de) | Verfahren zur herstellung von polyamiden | |
| ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
| DE602004000313D1 (de) | Verfahren zur Verfügungstellung von ozonenthaltendem Wasser | |
| DE60325381D1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
| DE602004020895D1 (de) | Verfahren zur herstellung von kohlenstoffnanospulen | |
| DE10390418D2 (de) | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen | |
| DE502004005626D1 (de) | Verfahren zur herstellung von organoacylphosphiten | |
| EP1899472A4 (de) | Geänderter glyoxylat-shunt zur verbesserten produktion von aspartat abgeleiteter aminosäuren und chemikalien | |
| DE60331111D1 (de) | Verfahren zur Herstellung von martensitaushärtendem Stahl | |
| EP1888106A4 (de) | Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen | |
| ATE456666T1 (de) | Verfahren zur auswertung von ribonukleotidsequenzen | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| ATA14432002A (de) | Verbessertes verfahren zur singlet sauerstoff oxidation von organischen substraten | |
| ATE468032T1 (de) | Verfahren zur verringerung von herbheit |